Publicaciones en colaboración con investigadores/as de Instituto Valenciano de Oncologia (14)

2024

  1. Efficacy and safety of cemiplimab in the treatment of advanced cutaneous squamous cell carcinoma: A multicentre real-world retrospective study from Spain and systematic review of the published data

    Journal of the European Academy of Dermatology and Venereology

  2. Melanoma Registry of the Spanish Academy of Dermatology and Venereology (REGESMEL): Description and Data in its First Year of Operation

    Actas Dermo-Sifiliograficas, Vol. 115, Núm. 7, pp. 663-669

2023

  1. Results in mediastinal lymph node staging of surgical lung cancer: Data from the prospective cohort of the Spanish Video-Assisted Thoracic Surgery Group

    Cirugia Espanola, Vol. 101, Núm. 6, pp. 408-416

  2. Sonidegib as a Locally Advanced Basal Cell Carcinoma Therapy in Real-life Clinical Setting: A National Multicentre Study

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 7, pp. T565-T571

2022

  1. Activity and safety of topical pimecrolimus in patients with early stage mycosis fungoides (PimTo-MF): a single-arm, multicentre, phase 2 trial

    The Lancet Haematology, Vol. 9, Núm. 6, pp. e425-e433

2019

  1. MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort

    The Lancet Child and Adolescent Health, Vol. 3, Núm. 5, pp. 332-342

2017

  1. Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 17, Núm. 3, pp. 186-191

2015

  1. MC1R gene variants and non-melanoma skin cancer: A pooled-analysis from the M-SKIP project

    British Journal of Cancer, Vol. 113, Núm. 2, pp. 354-363

  2. MC1R variants increased the risk of sporadic cutaneous melanoma in darker-pigmented Caucasians: A pooled-analysis from the M-SKIP project

    International Journal of Cancer, Vol. 136, Núm. 3, pp. 618-631

2013

  1. Registro nacional de melanoma cutáneo. Características del tumor en el momento del diagnóstico: 15 años de experiencia

    Actas Dermo-Sifiliograficas, Vol. 104, Núm. 9, pp. 789-799

2012

  1. First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study

    Onkologie, Vol. 6, Núm. 2, pp. 96-103

  2. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study

    Oncologist, Vol. 17, Núm. 1, pp. 15-25

  3. Melanocortin-1 receptor, skin cancer and phenotypic characteristics (M-SKIP) project: Study design and methods for pooling results of genetic epidemiological studies

    BMC Medical Research Methodology, Vol. 12

  4. Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

    PLoS ONE, Vol. 7, Núm. 10